How Long Does Adderall Last? IR vs XR — A Complete Guide

“How long does my Adderall last?” It sounds like a simple question, but the answer depends on which formulation you take, whether you ate breakfast, and how your individual body processes amphetamine. The difference between Adderall IR and Adderall XR is not just “short vs. long” — it is a fundamentally different delivery mechanism that produces a different timeline in your body.

This article walks through the pharmacokinetics of both formulations using data from FDA prescribing information and peer-reviewed studies. Every number is cited to a primary source. If you are looking for the same breakdown for methylphenidate-based medications, see our companion article: How Long Does Ritalin Last? IR vs LA vs Concerta.

What’s actually in Adderall

Adderall is not a single molecule. It contains four different amphetamine salts in equal proportions: dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate (Adderall IR FDA label). Two of these salts are pure dextro-isomer (d-amphetamine), and two are racemic (a 50/50 mix of d- and l-amphetamine).

The net result is a 3:1 ratio of d-amphetamine to l-amphetamine by salt weight. This matters because the two isomers have different pharmacological profiles. d-Amphetamine is approximately 3—7 times more potent at the dopamine transporter (DAT) than l-amphetamine, while l-amphetamine has relatively stronger norepinephrine activity (Heal et al., 2013). The combination is designed to provide both dopaminergic and noradrenergic effects.

Because d-amphetamine is the dominant driver of wake-promoting and focus-enhancing effects, the FocusCurve app applies an active fraction of 0.75 to Adderall doses (modeling only the d-amphetamine component). When you log 20 mg of Adderall, the app treats only the d-amphetamine portion (20 × 0.75 = 15 mg) as the active dose for its PK calculations. The remaining 25% as l-amphetamine is present in the body but is not tracked by the model.

Both Adderall IR (tablet) and Adderall XR (capsule) contain the same four salts in the same 3:1 d/l ratio. The difference is entirely in how the drug is delivered over time.

Adderall IR: how long it lasts

Adderall IR is a conventional immediate-release tablet. When you swallow it, all of the drug dissolves and enters your bloodstream in a single wave.

Peak and duration

Adderall IR reaches peak levels approximately 3 hours after ingestion (Adderall IR FDA label). The clinical effect — the period during which most people feel the medication working — lasts approximately 4 to 6 hours (StatPearls, NBK507808).

This is why many prescribers write Adderall IR as a twice- or three-times-daily medication, with doses spaced 4 to 6 hours apart. A single dose is not designed to cover an entire day.

The half-life is much longer than the clinical effect

Here is a point that confuses many people: the half-life of amphetamine is far longer than the clinical duration of a single IR dose.

Source: Adderall XR FDA label (half-life data applies to amphetamine regardless of formulation).

Note: FocusCurve models only the d-amphetamine fraction of Adderall, as d-amphetamine is the dominant wake-promoting enantiomer. The l-amphetamine half-life values above are from the FDA label but are not used in the app’s concentration calculations.

So if d-amphetamine has a 10-hour half-life, why does the IR effect only last 4—6 hours? Because “clinical effect” is determined by the concentration being above a certain threshold — not by the drug being completely gone. After the peak, levels decline. Once they drop below the level needed to produce a noticeable effect, the medication “wears off” — even though a substantial amount of amphetamine is still in your system. It just is not high enough to be therapeutically active.

This residual amphetamine is relevant for two reasons: it contributes to sleep disruption later in the evening, and it means a second dose builds on top of what is left from the first.

Adderall XR: the multi-pulse delivery system

Adderall XR uses a fundamentally different delivery strategy than a simple extended-release coating. Each capsule contains two types of drug-containing beads: immediate-release beads and delayed-release beads (Heal et al., 2013; Adderall XR FDA label).

The immediate-release beads dissolve right away, producing the first wave of absorption — identical to taking an IR tablet. The delayed-release beads have an enteric coating designed to dissolve at intestinal pH (~6.8). Rather than releasing all at once, these DR beads dissolve progressively over approximately 2 to 6 hours after dosing, producing a sustained plateau of absorption rather than a single second bolus. The net effect is a broad, sustained plasma profile that extends coverage well beyond what a single IR dose provides.

This delivery profile was compared to IR dosing in a study by Tulloch et al. (2002): Adderall XR 20 mg was bioequivalent to Adderall IR 10 mg taken twice, 4 hours apart in total exposure (AUC), confirming the extended-release design delivers the same total amount of drug over time.

Peak and duration

Because of the multi-pulse delivery system, Adderall XR reaches its peak later than IR:

• Tmax (fasted): approximately 5.2 hours for d-amphetamine
• Tmax (with a high-fat meal): approximately 7.7 hours for d-amphetamine — a delay of about 2.5 hours

(Adderall XR FDA label)

Note on the FocusCurve app: The app’s Phase Calculator, which drives the Status Lane UI (showing kick/peak/fade/cleared phases), uses slightly different tmax values for its time-since-dose classification: 7 hours fasted and 9.5 hours with food for Adderall XR. These phenomenological timestamps are calibrated against broader PK-PD literature rather than the FDA label alone, reflecting the documented lag between plasma levels and pharmacodynamic effect (Dolder et al., 2017; Brauer et al., 1996). The FDA label values above remain the regulatory-standard PK references.

The clinical duration of Adderall XR is 8 to 12 hours. An analog classroom study by McCracken et al. (2003) assessed children with ADHD every 1.5 hours over 12 hours and found that Adderall XR 20 and 30 mg showed significant effects from 1.5 hours through 10.5 and 12 hours post-dose, while a single IR dose waned by the afternoon. In its sleep-prediction model, FocusCurve uses exactly 12 hours for the Adderall XR duration window (based on the 30 mg McCracken data), with an effective sleep delay of 13 hours with the naive-user buffer or 14.5 hours when food is logged with the dose.

Can you open the capsule?

Yes. The Adderall XR capsule can be opened and the entire contents sprinkled on applesauce, then consumed immediately without chewing. A bioavailability study by Tulloch et al. (2002) confirmed that this sprinkle method is bioequivalent to swallowing the intact capsule — both the rate and extent of absorption are the same. The beads should not be crushed or chewed, and the food should be consumed immediately.

Side-by-side comparison

Sources: Adderall IR FDA label; Adderall XR FDA label; StatPearls.

Why it feels different some days

If you have ever felt like your Adderall “didn’t work today” or “wore off early,” there are several pharmacological reasons why — none of which mean the medication is defective or that you are imagining things.

Food effects

For Adderall XR, a high-fat meal delays peak d-amphetamine levels by approximately 2.5 hours (from 5.2 h fasted to 7.7 h with food) without changing the total amount absorbed (Adderall XR FDA label). In the FocusCurve app, this delay is modeled through two mechanisms: first, food slows the absorption rate of all beads (~20% reduction in ka); second, the delayed-release beads spend more time in the stomach before reaching the intestinal pH (~6.8) needed to dissolve their enteric coating, shifting the entire delayed-release window approximately 2.5 hours later. The total duration may shift later rather than being shorter, but the subjective experience of a “slow start” can feel like the medication is not working.

For Adderall IR, food effects have not been formally studied (Adderall IR FDA label), but general pharmacological principles suggest that food may delay absorption similarly. The FocusCurve app applies a food-effect adjustment for Adderall IR (slowing the absorption rate by approximately 30%, ka×0.7) based on these principles.

Urine pH: the hidden variable

This is one of the most underappreciated factors affecting how long amphetamine lasts. According to the FDA label, urinary recovery of amphetamine ranges from 1% to 75% depending on urinary pH. Amphetamine has a pKa of 9.9, meaning it is a basic compound. In acidic urine, more amphetamine becomes ionized and is excreted faster. In alkaline urine, less is ionized and more is reabsorbed back into the bloodstream.

In practical terms: if your urine is more acidic on a given day — due to diet (high protein, cranberry juice, vitamin C), dehydration, or other factors — your body may clear amphetamine faster, making the medication feel like it wears off sooner. If your urine is more alkaline, the medication may last longer. This variability is real and significant enough to be documented in the FDA label.

Individual metabolism: CYP2D6

Amphetamine is partially metabolized by CYP2D6, a liver enzyme responsible for converting amphetamine to 4-hydroxy-amphetamine (Adderall XR FDA label). CYP2D6 activity varies significantly between individuals based on genetics. A subset of the population are CYP2D6 poor metabolizers, meaning they break down amphetamine more slowly and may experience higher levels for longer.

A study by Gerlach et al. (2024) found that CYP2D6 poor metabolizers had 3.67 times higher odds of reporting symptom improvement compared to intermediate metabolizers, consistent with higher drug exposure. The practical implication: two people taking the same dose can have meaningfully different drug levels simply because of genetic differences in this one enzyme.

Dose proportionality and tolerance

Adderall exhibits linear (dose-proportional) pharmacokinetics — doubling the dose approximately doubles the peak and total exposure (Adderall IR FDA label). This means dose adjustments produce predictable changes in drug levels. If you feel the medication is less effective over time, this may reflect pharmacodynamic tolerance (your brain adapting to the drug) rather than a change in how your body processes it.

How Adderall compares to Vyvanse

Vyvanse (lisdexamfetamine) is often compared to Adderall because both contain amphetamine. But there are three key differences in how they work.

1. Vyvanse is a prodrug

Lisdexamfetamine is d-amphetamine chemically bonded to the amino acid l-lysine. This bonded form is pharmacologically inactive — it must be cleaved to release active d-amphetamine. This conversion happens primarily in red blood cells through enzymatic hydrolysis, not in the liver or gut (Vyvanse FDA label). This rate-limiting step produces a more gradual, consistent rise in d-amphetamine levels compared to taking d-amphetamine directly.

A separate conversion is needed at the molecular level: lisdexamfetamine dimesylate (~455.6 g/mol) contains d-amphetamine free base (~135.2 g/mol) as only about 30% of its mass (conversion factor 0.2968). This means 70 mg of Vyvanse yields approximately 20.8 mg of active d-amphetamine base — comparable to the d-amphetamine content of roughly 28 mg of Adderall (which delivers 75% of its labeled dose as d-amphetamine). FocusCurve applies this molar mass conversion in its Vyvanse model.

2. Vyvanse contains only d-amphetamine

Unlike Adderall’s 3:1 mixture of d- and l-amphetamine, Vyvanse releases only d-amphetamine. There is no l-amphetamine component. This means the pharmacological profile is purely dopamine-preferring, without the additional noradrenergic contribution of l-amphetamine.

3. Vyvanse lasts longer

The clinical duration of Vyvanse is approximately 13 hours in children (Wigal et al., 2009) and 14 hours in adults (Ermer et al., 2016), compared to Adderall XR’s 8—12 hours. This longer duration comes from the prodrug conversion step, which extends the time over which active d-amphetamine enters the bloodstream. FocusCurve uses exactly 14 hours for the Vyvanse duration window (based on the adult Ermer et al. data), with an effective sleep delay of 15 hours when the +1 hour naive-user buffer is applied.

Sources: Adderall XR FDA label; Vyvanse FDA label; Ermer et al., 2016; Wigal et al., 2009.

A head-to-head PK study by Dolder et al. (2017) compared equimolar doses of lisdexamfetamine and d-amphetamine IR in healthy volunteers. The key finding: both produced similar total d-amphetamine exposure (AUC), similar peak concentrations, and similar half-lives (~7.9 hours), but lisdexamfetamine had a delayed onset (~1 hour later). The d-amphetamine half-life was the same because it is the same molecule — the prodrug simply changes how it enters the bloodstream, not how it is eliminated.

Sleep implications

The long half-life of amphetamine (10—13 hours) means that the molecule persists in your body well beyond the period when you feel it working. This has direct consequences for sleep.

In FDA clinical trials, 27% of adults on Adderall XR reported insomnia compared to 13% on placebo. For Vyvanse, the rate was also 27% versus 8% on placebo. Both FDA labels explicitly recommend morning dosing and advise against afternoon doses due to insomnia risk.

Why plasma levels don’t tell the whole story

An important and often misunderstood point: the amphetamine molecule persists in your plasma long after you stop feeling its effects. This PK-PD disconnect — where pharmacokinetics (drug levels in blood) and pharmacodynamics (clinical effect) are out of sync — is well-documented for amphetamine. Dolder et al. (2017) demonstrated clockwise hysteresis: plasma levels of d-amphetamine remain elevated while subjective effects have already declined substantially. Brauer et al. (1996) observed the same pattern earlier with d-amphetamine in healthy volunteers.

Because of this disconnect, the FocusCurve app does not use plasma concentration thresholds to predict amphetamine sleep-readiness. Instead, it uses FDA-label-anchored clinical duration windows:

• Adderall IR: 6-hour felt-duration window (StatPearls, NBK507808)
• Adderall XR: 12-hour felt-duration window (McCracken et al., 2003)
• Vyvanse: 14-hour felt-duration window (Ermer et al., 2016)

The app adds a +1 hour buffer for amphetamine-naive users (lower tolerance → longer perceived duration) and a +1.5 hour food shift when food is logged with the dose (reflecting the delayed-release bead retention in the stomach). For a typical new user taking Adderall XR with breakfast, the app would predict sleep-readiness approximately 14.5 hours post-dose (12h + 1h buffer + 1.5h food shift), regardless of how much amphetamine remains in plasma.

If you are adding caffeine on top of amphetamine, the effects on wakefulness are additive. Caffeine has its own half-life of approximately 5 hours and is metabolized by a completely different enzyme (CYP1A2), so there is no pharmacokinetic interaction — but the two stimulants together produce more total stimulation than either alone.

For a detailed breakdown of these sleep dynamics, including evidence-based strategies for managing stimulant-related insomnia, see our articles on sleep and ADHD medication and caffeine and ADHD medication.

Frequently asked questions

References

1. Adderall (mixed amphetamine salts) prescribing information. dailymed.nlm.nih.gov
2. Adderall XR (mixed amphetamine salts ER) prescribing information. dailymed.nlm.nih.gov
3. Vyvanse (lisdexamfetamine dimesylate) prescribing information. dailymed.nlm.nih.gov
4. Dextroamphetamine-Amphetamine. StatPearls, NCBI Bookshelf. ncbi.nlm.nih.gov
5. Heal DJ, et al. Amphetamine, past and present — a pharmacological and clinical perspective. J Psychopharmacol. 2013;27(6):479-496. pmc.ncbi.nlm.nih.gov
6. Tulloch SJ, et al. SLI381 (Adderall XR) bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy. 2002;22(11):1405-15. pubmed.ncbi.nlm.nih.gov
7. McCracken JT, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42(6):673-83. pubmed.ncbi.nlm.nih.gov
8. Dolder PC, et al. Pharmacokinetics and pharmacodynamics of lisdexamfetamine compared with d-amphetamine in healthy subjects. Front Pharmacol. 2017;8:617. pmc.ncbi.nlm.nih.gov
9. Wigal SB, et al. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with ADHD. Child Adolesc Psychiatry Ment Health. 2009;3(1):17. pmc.ncbi.nlm.nih.gov
10. Ermer JC, et al. Lisdexamfetamine dimesylate: prodrug delivery, amphetamine exposure and duration of efficacy. Clin Drug Investig. 2016;36:341-356. pubmed.ncbi.nlm.nih.gov
11. Gerlach S, et al. Effect of CYP2D6 genetic variation on patient-reported outcomes among children treated with amphetamines. Pharmacogenet Genomics. 2024;34(5):149-153. pubmed.ncbi.nlm.nih.gov
12. Brauer LH, et al. Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men. J Clin Psychopharmacol. 1996;16(1):72-76. pubmed.ncbi.nlm.nih.gov